Viatris Lifts 2026 Outlook After Strong Second Quarter

{
  "signal_id": "104e0888-3355-f0f5-ad10-21efa3356217",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-08-07T12:34:00+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "url": "https://www.theglobeandmail.com/investing/markets/stocks/VTRS-Q/pressreleases/3718207/viatris-lifts-2026-outlook-after-strong-second-quarter/",
    "title": "Viatris Lifts 2026 Outlook After Strong Second Quarter - The Globe and Mail",
    "excerpt": "Viatris ( (VTRS) ) has issued an update. Viatris reported its second-quarter 2026 results on August 6, 2026, posting total revenues of $3.76 billion, up 5% year over year, with operational growth of 3.5%, and an adjusted EBITDA of $1.2 billion, up 8% operationally, despite a U.S. GAAP net loss of $119 million. The company highlighted strong performance in Greater China, announced U.S. FDA approval of Gwyn Lo, the sale of global rights to Tyrvaya, raised full-year 2026 financial guidance midpoints for all metrics, returned about $550 million to shareholders and reduced its gross leverage ratio to 2.9x, underscoring improved balance sheet strength and continued capital returns. Management attributed the quarter’s performance to disciplined commercial execution and pipeline progress, noting that first-half momentum supports increased confidence in full-year targets. By combining portfolio reshaping, including the Tyrvaya divestiture, with ongoing share repurchases and debt reduction, Viatris is positioning itself for more balanced operations in the second half of 2026 and signaling a focus on long-term value creation for both patients and shareholders. The most recent analyst rating on (VTRS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page . Spark’s Take on VTRS Stock According to Spark...",
    "summary": "Viatris reported an adjusted EBITDA of $1.2 billion for the second quarter of 2026, up 8% operationally.",
    "location": "Pittsburgh, Pennsylvania, USA",
    "planning": false,
    "image_url": "https://www.theglobeandmail.com/pf/resources/assets/meta/twitter-summary-240x240.png?d=939",
    "confidence": 0.95,
    "published_at": "2026-08-07T12:34:00Z",
    "location_data": [
      {
        "city": "Pittsburgh",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Viatris reported its second-quarter 2026 results on August 6, 2026, posting total revenues of $3.76 billion, up 5% year over year, with operational growth of 3.5%, and an adjusted EBITDA of $1.2 billion, up 8% operationally, despite a U.S. GAAP net loss of $119 million.",
    "amount_normalized": 1200000000
  }
}

curl https://signals.autobound.ai/v1/signals/104e0888-3355-f0f5-ad10-21efa3356217 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","limit":20}'